LS predisposes to cancer in multiple organs, including colorectal, endometrial, upper GI, genitourinary, brain, and skin cancers.
Unfortunately, most individuals with LS remain undiagnosed4 and do not benefit from the growing medicines, equipment, and techniques available of early detection and prevention strategies that can prolong life, reduce cancer incidence, and thereby increase quality of life for individuals with LS.
In spite of the numerous diagnostic approaches to identifying individuals and families with LS, however, it is widely understood that LS remains underdiagnosed and thus opportunities for genetically driven cancer prevention remain missed.
The EHR(Electronic Health Record) can play an important role in identifying candidates for LS screening and advancing the clinical care of patients with LS. However, many limitations of the EHR need to be addressed and complementary approaches that incorporate input from all stakeholders are key to improving the lives of individuals with LS.
Lynch Syndrome Ireland 